EU’s Decision On Moderna’s COVID-19 Shot For Younger Kids Expected In Two Months
The European Medicines Agency expects to decide in about two months whether to allow the use of Moderna Inc’s (NASDAQ:MRNA) COVID-19 vaccine…
Watching Moderna Shares Following NY Times Article ‘Moderna and U.S. at Odds Over Vaccine Patent Rights’
https://www.nytimes.com/2021/11/09/us/moderna-vaccine-patent-nih.html
Where Moderna Stands With Analysts
Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:
Wolfe Research Initiates Coverage On Moderna with Outperform Rating, Announces Price Target of $304
Wolfe Research initiates coverage on Moderna (NASDAQ:MRNA) with a Outperform rating and announces Price Target of $304.
When Winning Streaks Stop: Trying To Beat The Market By Buying Stocks Like Tesla
Teslas getting charged in a Wawa parking lot last month. Photo via author.
When Winning Streaks Stop
SVB Leerink Maintains Underperform on Moderna, Raises Price Target to $86
SVB Leerink analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and raises the price target from $85 to $86.
Barclays Maintains Overweight on Moderna, Lowers Price Target to $404
Barclays analyst Gena Wang maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $463 to $404.